Eli Lilly and Company (NYSE:LLY) Shares Bought by National Pension Service

National Pension Service boosted its stake in Eli Lilly and Company (NYSE:LLY) by 2.2% in the fourth quarter, Holdings Channel reports. The fund owned 1,299,416 shares of the company’s stock after buying an additional 27,550 shares during the quarter. Eli Lilly and Company makes up about 1.1% of National Pension Service’s holdings, making the stock its 14th biggest holding. National Pension Service’s holdings in Eli Lilly and Company were worth $757,456,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of LLY. Baystate Wealth Management LLC grew its position in shares of Eli Lilly and Company by 26.1% during the third quarter. Baystate Wealth Management LLC now owns 953 shares of the company’s stock worth $512,000 after buying an additional 197 shares in the last quarter. North Point Portfolio Managers Corp OH increased its holdings in shares of Eli Lilly and Company by 13.4% in the 3rd quarter. North Point Portfolio Managers Corp OH now owns 525 shares of the company’s stock valued at $282,000 after acquiring an additional 62 shares during the last quarter. IFM Investors Pty Ltd raised its position in shares of Eli Lilly and Company by 3.0% during the 3rd quarter. IFM Investors Pty Ltd now owns 164,045 shares of the company’s stock valued at $88,113,000 after acquiring an additional 4,790 shares in the last quarter. High Note Wealth LLC lifted its stake in Eli Lilly and Company by 4.7% during the third quarter. High Note Wealth LLC now owns 4,021 shares of the company’s stock worth $2,160,000 after purchasing an additional 181 shares during the last quarter. Finally, Waldron Private Wealth LLC boosted its holdings in Eli Lilly and Company by 0.7% in the third quarter. Waldron Private Wealth LLC now owns 13,838 shares of the company’s stock worth $7,433,000 after purchasing an additional 95 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded down $2.70 on Thursday, hitting $772.30. The company’s stock had a trading volume of 989,729 shares, compared to its average volume of 3,053,336. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The stock’s 50 day moving average is $761.22 and its 200-day moving average is $674.88. The company has a market capitalization of $734.00 billion, a PE ratio of 114.27, a PEG ratio of 1.45 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.62 earnings per share. Equities research analysts expect that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 10th. Stockholders of record on Thursday, May 16th will be paid a $1.30 dividend. The ex-dividend date is Wednesday, May 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.67%. Eli Lilly and Company’s payout ratio is currently 76.58%.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Barclays increased their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.